Characterization of prostate-specific antigen binding peptides selected by phage display technology

Journal of Molecular Recognition

Volumn 19, Issue 1, 2006, Pages 10-20

  Ferrieu Weisbuch, Catherine ^a   Michel, Sandrine ^a   Collomb Clerc, Emilie ^a   Pothion, Catherine ^a   Deléage, Gilbert ^b   Jolivet Reynaud, Colette ^a  

^a BIOMÉRIEUX   (France)

^b INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

Author keywords

Cancer; Diagnosis; Enzymatic activity; Mimotope; Phage display peptide library; PSA

Indexed keywords

MONOCLONAL ANTIBODY; PEPTIDE; PEPTIDE LIBRARY; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; BLOOD; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; INSTRUMENTATION; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BINDING SITES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROTEIN BINDING;

EID: 31144431898     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.762     Document Type: Article

References (28)

1. Carvalho AL, Sanz L, Barettino D, Romero A, Calvete JJ, Romao MJ. 2002. Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA. J. Mol. Biol. 322: 325-337.
2. Charrier JP, Tournel C, Michel S, Comby S, Jolivet-Reynaud C, Passagot J, Dalbon P, Chautard D, Jolivet M. 2001. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis 22: 1861-1866.
3. Charrier JP, Tournel C, Michel S, Dalbon P, Jolivet M. 1999. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia. Electrophoresis 20: 1075-1081.
4. Christensson A, Lilja H. 1994. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur. J. Biochem. 220: 45-53.
5. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. 1997. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res. 57: 4924-4930.
6. Frank R, Doring R. 1988. Simultaneous multiple peptide synthesis under continuous flow conditions on cellulose paper discs as segmental solid synthesis. Tetrahedron 44: 6031-6040.
7. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. 1983. LNCaP model of human prostatic carcinoma. Cancer Res. 43: 1809-1818.
8. Jolivet-Reynaud C, Adida A, Michel S, Deleage G, Paranhos-Baccala G, Gonin V, Battail-Poirot N, Lacoux X, Rolland D. 2004. Characterization of mimotopes mimicking an immunodominant conformational epitope on the hepatitis C virus NS3 helicase. J. Med. Virol. 72: 385-395.
9. Jolivet-Reynaud C, Dalbon P, Viola F, Yvon S, Paranhos-Baccala G, Piga N, Bridon L, Trabaud MA, Battail N, Sibai G, Jolivet M. 1998. HCV core immunodominant region analysis using mouse monoclonal antibodies and human sera: characterization of major epitopes useful for antigen detection. J. Med. Virol. 56: 300-309.
10. Jolivet-Reynaud C, Lesenechal M, O'Donnell B, Becquart L, Foussadier A, Forge F, Battail-Poirot N, Lacoux X, Carman W, Jolivet M. 2001. Localization of hepatitis B surface antigen epitopes present on variants and specifically recognised by anti-hepatitis B surface antigen monoclonal antibodies. J. Med. Virol. 65: 241-249.
11. Jolivet-Reynaud C, Perron H, Ferrante P, Becquart L, Dalbon P, Mandrand B. 1999. Specificities of multiple sclerosis cerebrospinal fluid and serum antibodies against mimotopes. Clin. Immunol. 93: 283-293.
12. Lee B, Richards FM. 1971. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55: 379-400.
13. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T. 1991. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37: 1618-1625.
14. Lundwall A, Lilja H. 1987. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 214: 317-322.
15. Michel S, Charrier JP, Deleage G, Battail-Poirot N, Jolivet M, Jolivet-Reynaud C. 2001a. Analysis of prostate specific antigen and alpha1-antichymotrypsin interaction using antipeptide monoclonal antibodies. J. Urol. 165: 301-306.
16. Michel S, Collomb-Clerc E, Geourjon C, Charrier JP, Passagot J, Courty Y, Deleage G, Jolivet-Reynaud C. 2005. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies. J. Mol. Recognit. 18: 225-235.
17. Michel S, Deleage G, Charrier JP, Passagot J, Battail-Poirot N, Sibai G, Jolivet M, Jolivet-Reynaud C. 1999. Anti-free prostate-specific antigen monoclonal antibody epitopes defined by mimotopes and molecular modeling. Clin. Chem. 45: 638-650.
18. Michel S, Forest E, Petillot Y, Deleage G, Heuze-Vourc'h N, Courty Y, Lascoux D, Jolivet M, Jolivet-Reynaud C. 2001b. Involvement of the C-terminal end of the prostrate-specific antigen in a conformational epitope: characterization by proteolytic degradation of monoclonal antibody-bound antigen and mass spectrometry. J. Mol. Recognit. 14: 406-413.
19. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, Evans CL, Gasior CL, Linton HJ, Carpenter P, Rittenhouse HG. 2001. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 61: 6958-6963.
20. Niemela P, Lovgren J, Karp M, Lilja H, Pettersson K. 2002. Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. Clin. Chem. 48: 1257-1264.
21. Pakkala M, Jylhasalmi A, Wu P, Leinonen J, Stenman UH, Santa H, Vepsalainen J, Perakyla M, Narvanen A. 2004. Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity. J. Pept. Sci. 10: 439-447.
22. Scott JK, Smith GP. 1990. Searching for peptide ligands with an epitope library. Science 249: 386-390.
23. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. 1987. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317: 909-916.
24. Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P, Huland H, Lilja H. 2002. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J. Urol. 168: 1917-1922.
25. Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH. 2000. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur. J. Biochem. 267: 6212-6220.
26. Wu P, Stenman UH, Pakkala M, Narvanen A, Leinonen J. 2004a. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Prostate 58: 345-353.
27. Wu P, Zhu L, Stenman UH, Leinonen J. 2004b. Immunopeptidometric assay for enzymatically active prostate-specific antigen. Clin. Chem. 50: 125-129.
28. Zhu L, Leinonen J, Zhang WM, Finne P, Stenman UH. 2003. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha(1)-antichymotrypsin complex together with free or total PSA. Clin. Chem. 49: 97-103.